New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:43 EDTMRKMerck announces presentation of data evaluating pembrolizumab
Merck announced the first presentation of data evaluating pembrolizumab, Merck’s investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer. In previously-untreated patients, the objective response rate with pembrolizumab as a single-agent was 47% by investigator-assessed, immune-related response criteria and 26% by centrally evaluated RECIST v1.1. In evaluable patients who had measurable disease with one post baseline scan, 80% demonstrated tumor shrinkage as measured by centrally evaluated RECIST criteria. The median duration of response has not been reached, with some patients continuing on treatment with pembrolizumab as monotherapy for at least one year.
News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:57 EDTMRKCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 13, 2014
18:02 EDTMRKMerck provides statement on role of PNEUMOVAX 23 in updated ACIP recommendations
Subscribe for More Information
16:52 EDTMRKMerck confirms FDA approval of BELSOMRA
Subscribe for More Information
15:30 EDTMRKFDA approves Belsomra sleep drug
The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use